RxDoctor Payments Data

Lindsay McCarthy, APRN

Family · Helena, MTNPI 1184956625

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.6% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 38.7% of the total. Among family clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,275in general payments, 2019–2025

Across 159 payments — averaging $14.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$881
  • Amgen$379
  • Johnson & Johnson$212
  • Lilly USA, LLC$171
  • Novartis$134
  • Sanofi$101
  • plus $397 from 9 others

What the payments were for

  • Food & beverage$2,17596%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,275 in reported general payments places this provider in the 90th percentile of 481 family providers in Montana.

See all family providers in Montana

Medicare billing

Part B allowed, 2024
$68,881
Medicare patients
381
Services billed
1,143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SotyktuDeucravacitinib11$70,723
Clobetasol Propionate38$1,404
Betamethasone Dipropionate32$1,141
Metronidazole14$898
Triamcinolone Acetonide57$626
Minocycline Hcl21$549
Clindamycin Phosphate24$534
Spironolactone27$478
ValacyclovirValacyclovir Hcl18$363
Ketoconazole29$322
Mometasone Furoate21$280
Nystatin11$214
Mupirocin26$198
Amoxicillin11$88
Hydroxyzine Hcl14$48

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Sotyktu$86$70,72311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 481 family providers in Montana.

Other family in Helena

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →